6-(4-methoxy-phenyl)-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one | 1005402-85-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 6-(4-methoxy-phenyl)-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one
• 英文别名: 6-(4-methoxyphenyl)-2-pyridin-2-yl-4,5-dihydropyridazin-3-one
• CAS: 1005402-85-6
• 化学式: C₁₆H₁₅N₃O₂
• 分子量: 281.314
• InChiKey: JSIBPGHKWGXCIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(4-methoxy-phenyl)-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以93%的产率得到6-(4-hydroxy-phenyl)-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one
  参考文献：
  名称：

  Pyridizinone derivatives

  摘要：

  本发明提供了式(I*)的化合物：它们作为H3抑制剂的用途，其制备方法以及药物组合物。

  公开号：

  US20080027041A1
• 作为产物：
  描述：

  2-肼吡啶 、 3-(4-甲氧基苯甲酰基)丙酸 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 反应 2.0h， 生成 6-(4-methoxy-phenyl)-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one
  参考文献：
  名称：

  Pyridizinone derivatives

  摘要：

  本发明提供了式(I*)的化合物：它们作为H3抑制剂的用途，其制备方法以及药物组合物。

  公开号：

  US20080027041A1

文献信息

• Pyridazinone Derivatives
  申请人：Bacon Edward R.

  公开号：US20110288075A1

  公开（公告）日：2011-11-24

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

  本发明涉及新型吡啶并咪唑酮衍生物，可介导酶活性。特别是，这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性，包括神经退行性疾病、睡眠/清醒障碍、注意力缺陷多动障碍和认知/认知障碍等。
• PYRIDAZINONE DERIVATIVES
  申请人：Bacon Edward R.

  公开号：US20140142088A1

  公开（公告）日：2014-05-22

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.

  本发明涉及新型吡啶酮衍生物，可介导酶活性。特别地，这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性，包括但不限于神经退行性疾病、睡眠/觉醒障碍、注意力缺陷多动障碍和认知方面。
• Aryl pyridazinone derivatives and their use as H3 receptor ligands
  申请人：Bacon Edward R.

  公开号：US08586588B2

  公开（公告）日：2013-11-19

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

  本发明涉及新型吡啶并咪唑酮衍生物，可介导酶活性。特别是，这些化合物及/或其药学上可接受的盐可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面有效，包括神经退行性疾病、睡眠/觉醒障碍、注意力缺陷多动症和认知/认知障碍等。
• Pyridizinone Derivatives
  申请人：Cephalon, Inc.

  公开号：EP2492263A1

  公开（公告）日：2012-08-29

  The present invention provides compounds of formula (I*): their use as H3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

  本发明提供了式 (I*) 的化合物： 它们作为 H3 抑制剂的用途、制备工艺及其药物组合物。
• Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity
  作者：Robert L. Hudkins、Lisa D. Aimone、Thomas R. Bailey、Robert J. Bendesky、Reddeppa reddy Dandu、Derek Dunn、John A. Gruner、Kurt A. Josef、Yin-Guo Lin、Jacquelyn Lyons、Val R. Marcy、Joanne R. Mathiasen、Babu G. Sundar、Ming Tao、Allison L. Zulli、Rita Raddatz、Edward R. Bacon

  DOI：10.1016/j.bmcl.2011.06.108

  日期：2011.9

  H3R structure-activity relationships on a novel class of pyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modifications of the pyridazinone core, central phenyl ring and linker led to the identification of molecules with excellent target potency, selectivity and pharmacokinetic properties. Compounds 13 and 21 displayed potent functional H3R antagonism in vivo in the rat dipsogenia model and demonstrated robust wake activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.